Prevention of meningococcal serogroup C disease by NeisVac-C™

Raymond Borrow*, Jamie Findlow

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Citations (Scopus)


NeisVac-C™ has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. NeisVac-C was demonstrated to enhance responses to Haemophilus influenzae type b (Hib) polyribosylribitol phosphate when coadministered with Hib-tetanus toxoid conjugate vaccines. NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine.

Original languageEnglish
Pages (from-to)265-279
Number of pages15
JournalExpert Review of Vaccines
Issue number3
Publication statusPublished - Mar 2009

Bibliographical note

Funding Information:
• Meningitis Research Foundation of Canada


  • Efficacy
  • Herd immunity
  • Immunogenicity
  • Meningococcal serogroup C conjugate vaccine
  • NeisVac-C™
  • Reactogenicity


Dive into the research topics of 'Prevention of meningococcal serogroup C disease by NeisVac-C™'. Together they form a unique fingerprint.

Cite this